Drug Trial Radar · NCT05476939
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
433
Planned (sponsor's estimate)
Start
Sep 29, 2022
Primary completion
Sep 2028
Study completion Sep 2031
Sponsor
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Innovative Therapies For Children with Cancer Consortium; Ministry of Health, France; Jazz Pharmaceuticals
- First posted
- Jul 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in comparison with everolimus (primary objective based on internal comparison) and subsequently to historical controls. Two treatment groups will be compared. A switch between treatment groups is allowed after confirmation of the disease progression (real-time central review blinded to the treatment arm allocation). Study treatment will be continued until centrally confirmed disease progression (either radiologically or histologically), unacceptable toxicity or consent withdrawal. The final conclusion of the trial will be successful for ONC201, if ONC201 is found significantly superior to everolimus in terms of centrally-reviewed PFS (Progression-free survival) from randomization (internal comparison) either overall, considering ND-DMG and DIPG-patients together, or in the subgroup of ND-DMG patients alone. In other cases, Everolimus will remain the standard arm unless it appears associated with an excess of toxicity compared to ONC201 which could then be discussed as a new standard.
Conditions
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
- Diffuse Midline Glioma, H3K27-altered
Interventions
EverolimusDrug
Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.
ONC201Drug
Capsules of 125mg. The prescribed dose is 375mg/m², orally, once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.
RadiotherapyRadiation
All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin. Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice. In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: Until 2 years after inclusion of the last patient
Locations
56 sites in 8 countries. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc (CUSL)
Brussels, Belgium · Recruiting
University Hospital Leuven (UZ Leuven)
Leuven, Belgium · Recruiting
Aarhus Universitetshospital Skejby
Aarhus, Denmark · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
H.C. Andersen Children's Hospital, Odense Universitetshospital
Odense, Denmark · Recruiting
Helsinki University Hospital
Helsinki, Finland · Recruiting
CHU d'Amiens-Picardie Site Sud
Amiens, France · Recruiting
Institut de Cancérologie de l'Ouest (ICO) - Site Paul Papin
Angers, France · Recruiting
CHU d'Angers - Bâtiment Robert Debré
Angers, France · Recruiting
CHU Besançon - Hôpital Jean Minjoz
Besançon, France · Recruiting
CHU de Bordeaux - Groupe hospitalier Saint André - Hôpital Saint André
Bordeaux, France · Recruiting
CHU de Bordeaux - Groupe hospitalier Pellegrin - Hôpital des enfants
Bordeaux, France · Recruiting
CHRU de Brest - Hôpital Morvan
Brest, France · Recruiting
CHU de Caen - Hôpital Côte de Nacre
Caen, France · Recruiting
CHU Estaing
Clermont-Ferrand, France · Recruiting
Centre Jean Perrin
Clermont-Ferrand, France · Recruiting
CHU François Mitterrand
Dijon, France · Recruiting
CHU Grenoble Alpes - Hôpital Albert Michallon
Grenoble, France · Not yet recruiting
CHU Grenoble Alpes - Hôpital Couple-Enfant
Grenoble, France · Recruiting
Centre Oscar Lambret
Lille, France · Recruiting
Hôpital Roger Salengro
Lille, France · Not yet recruiting
Hôpital de la mère et de l'enfant
Limoges, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Hôpital Pierre Wertheimer
Lyon, France · Recruiting
Hôpital de La Timone
Marseille, France · Recruiting
Hôpital Arnaud de Villeneuve
Montpellier, France · Recruiting
CHRU Nancy - Hôpital central
Nancy, France · Recruiting
CHRU Nancy Brabois - Hôpital d'enfants
Nancy, France · Recruiting
CHU de Nice - Hôpital Pasteur 2
Nice, France · Recruiting
CHU de Nice - Hôpital L'Archet 2
Nice, France · Recruiting
Hôpital Saint Louis
Paris, France · Recruiting
Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix
Paris, France · Recruiting
Institut Curie
Paris, France · Recruiting
CHU Poitiers
Poitiers, France · Recruiting
CHU de Reims - American Memorial Hospital 2
Reims, France · Recruiting
Centre Eugène Marquis
Rennes, France · Recruiting
CHU Rennes - Hôpital Sud
Rennes, France · Recruiting
CHU Rouen Normandie - Hôpital Charles-Nicolle
Rouen, France · Recruiting
CHU de Saint-Denis de La Réunion
Saint-Denis, France · Recruiting
CHU de Saint-Etienne - Hôpital Nord
Saint-Etienne, France · Recruiting
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.